| Property | Value |
|---|
|
?:abstract
|
-
BACKGROUND COVID-19 convalescent plasma (CCP) received an Emergency Use Authorization by the FDA. CCP with a signal-to-cutoff ratio of ≥12 using the Ortho VITROS SARS-CoV-2 IgG test (OVSARS2IgG) is permitted to be labeled \'high titer\'. Little is known about the relationship between OVSARS2IgG ratio and neutralizing capacity of plasma/sera against genuine SARS-CoV-2 virus. METHODS 981 samples from 196 repeat CCP donors 0-119 days post initial donation (DPID) were analyzed. Neutralizing capacity was assessed for 50% (PRNT50) and 90% (PRNT90) reduction of infectious virus using the gold standard plaque reduction neutralization test (PRNT). A subset of 91 donations were evaluated by OVSARS2IgG and compared to PRNT titers for diagnostic accuracy. RESULTS 32.7%/79.5% (PRNT90/PRNT50) of donations met a 1:80 titer initially but only 14.0%/48.8% (PRNT90/PRNT50) met this cut-off ≥85 DPID. Correlation of OVSARS2IgG results to neutralizing capacity allowed extrapolation to CCP therapy results. CCP with OVSARS2IgG ratios equivalent to a therapeutically beneficial group had neutralizing titers of ≥1:640 (PRNT50) and/or ≥1:80 (PRNT90). Specificity and positive predictive value of the OVSARS2IgG for qualifying highly neutralizing CCP was optimal using ratios significantly greater than the FDA cut-off. CONCLUSIONS This information provides a basis for refining the recommended properties of CCP used to treat COVID-19.
|
|
?:creator
|
|
|
?:doi
|
|
|
?:doi
|
|
|
?:journal
|
-
The_Journal_of_infectious_diseases
|
|
?:license
|
|
|
?:pmid
|
|
|
?:pmid
|
|
|
?:publication_isRelatedTo_Disease
|
|
|
?:source
|
|
|
?:title
|
-
Temporal Analysis of Serial Donations Reveals Decrease in Neutralizing Capacity and Justifies Revised Qualifying Criteria for COVID-19 Convalescent Plasma.
|
|
?:type
|
|
|
?:year
|
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}